Search

Displaying results 2481 - 2490 of 8696 in total
  1. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    Tiopronin may also be used to bind metal nanoparticles in Wilson's disease, which is an overload of copper in the body. … Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation.

  2. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with … [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia).

  3. Drug

    Propiomazine

    go.drugbank.com/drugs/DB00777
    Approved

    Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. … Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia.

    Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor Antagonists
  4. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. … It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Varlitinib

    go.drugbank.com/drugs/DB05944
    Investigational

    Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR.

  6. Drug

    Poliovirus type 2 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10796
    ApprovedInvestigational

    Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: Hexaxim Suspension for Injection, BOOSTRIX POLIO SUSPENSION FOR INJECTION
  7. Target

    Vascular endothelial growth factor receptor 3

    go.drugbank.com/bio_entities/BE0000023
    TargetHumans

    The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. … Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular

    Polypeptides: Vascular endothelial growth factor receptor 3Synonyms: Tyrosine-protein kinase receptor FLT4
  8. Target

    Receptor-type tyrosine-protein kinase FLT3

    go.drugbank.com/bio_entities/BE0000147
    TargetHumans

    Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells.

    Polypeptides: Receptor-type tyrosine-protein kinase FLT3Synonyms: FL cytokine receptor
  9. Target

    Sigma non-opioid intracellular receptor 1

    go.drugbank.com/bio_entities/BE0000290
    TargetHumans

    Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Regulates calcium efflux at the...

    Polypeptides: Sigma non-opioid intracellular receptor 1Synonyms: Sigma 1-type opioid receptor, Sigma non-opioid intracellular receptor 1
  10. Target

    Vascular endothelial growth factor receptor 2

    go.drugbank.com/bio_entities/BE0000369
    TargetHumans

    Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. … Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway.

    Polypeptides: Vascular endothelial growth factor receptor 2Synonyms: Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1